Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

573
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unraveling the Impacts of Preprocessing on the Metabolite Profile of Bitter Almond Using UPLC-MS/MS and GC-MS Analysis.

ACS omega·2026
Same author

Quasi-synchronization for complex networks with hybrid pinning intermittent control.

Neural networks : the official journal of the International Neural Network Society·2026
Same author

Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.

Nature medicine·2026
Same author

Hierarchical endpoints and win statistics for geromedicine trials.

Nature aging·2026
Same author

Cell stress and death liberate the autophagy-inhibitory tissue stress hormone DBI/ACBP into the circulation.

Autophagy·2026
Same author

Protein tyrosine kinases in dendritic cell-mediated anti-cancer immunity.

Seminars in immunology·2026

Related Experiment Video

Updated: Jul 25, 2025

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

11.6K

A Chemically Defined TLR3 Agonist with Anticancer Activity.

Julie Le Naour1,2, Sylvain Thierry3, Sarah Adriana Scuderi1,2,4

  • 1Centre de Recherche des Cordeliers, Equipe Labellisée Par la Ligue Contre le Cancer, Paris, France.

Oncoimmunology
|June 30, 2023
PubMed
Summary
This summary is machine-generated.

A novel Toll-like receptor 3 (TLR3) agonist, TL-532, demonstrates bioavailability and an acceptable safety profile in preclinical models. This double-stranded RNA compound stimulates immune responses, reducing bladder cancer growth and enhancing chemotherapy efficacy.

Keywords:
Cancer immunotherapydendritic cellsformyl peptide receptor 1immmunogenic cell death

More Related Videos

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.1K
Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.4K

Related Experiment Videos

Last Updated: Jul 25, 2025

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

11.6K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.1K
Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.4K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Toll-like receptor 3 (TLR3) agonists like polyinosinic:polycytidylic acid (poly(I:C)) show promise in cancer immunotherapy.
  • Poly(I:C) is used in clinical trials as an adjuvant to enhance tumor immunogenicity and overcome resistance to PD-L1 blockade.

Purpose of the Study:

  • To characterize the pharmacokinetic, pharmacodynamic, mechanistic, and toxicological profile of a novel TLR3 agonist, TL-532.
  • To evaluate the anticancer efficacy of TL-532 in preclinical models.

Main Methods:

  • TL-532, a chemically synthesized double-stranded RNA composed of poly(I:C) and polyadenylic-polyuridylic acid (poly(A:U)) blocks, was administered parenterally in preclinical models.
  • Pharmacokinetic, pharmacodynamic, mechanistic, and toxicological assessments were performed.
  • Anticancer efficacy was evaluated in bladder cancer and fibrosarcoma models, including immunodeficient mice.

Main Results:

  • TL-532 exhibited bioavailability and an acceptable toxicological profile.
  • TL-532 stimulated the production of chemokines and interleukins, serving as pharmacodynamic markers.
  • High-dose TL-532 monotherapy reduced bladder cancer growth in mice.
  • TL-532 restored immunogenic chemotherapy response in orthotopic fibrosarcoma in immunodeficient mice lacking formylpeptide receptor-1 (FPR1).

Conclusions:

  • TL-532 is a promising novel TLR3 agonist with potential as an anticancer immunotherapeutic agent.
  • Further development of TL-532 is warranted based on its preclinical profile and demonstrated efficacy.